4/16
08:09 am
anab
AnaptysBio, Inc. (NASDAQ: ANAB) is now covered by analysts at SVB Leerink LLC. They set an "outperform" rating and a $47.00 price target on the stock.
Low
Report
AnaptysBio, Inc. (NASDAQ: ANAB) is now covered by analysts at SVB Leerink LLC. They set an "outperform" rating and a $47.00 price target on the stock.
4/12
07:08 pm
anab
Why AnaptysBio Stock Zoomed Nearly 8% Higher This Week [Yahoo! Finance]
Medium
Report
Why AnaptysBio Stock Zoomed Nearly 8% Higher This Week [Yahoo! Finance]
4/11
07:28 am
anab
AnaptysBio, Inc. (NASDAQ: ANAB) is now covered by analysts at Wells Fargo & Company. They set an "overweight" rating and a $56.00 price target on the stock.
High
Report
AnaptysBio, Inc. (NASDAQ: ANAB) is now covered by analysts at Wells Fargo & Company. They set an "overweight" rating and a $56.00 price target on the stock.
4/1
10:15 am
anab
AnaptysBio, Inc. (NASDAQ: ANAB) had its price target lowered by analysts at JPMorgan Chase & Co. from $30.00 to $28.00. They now have a "neutral" rating on the stock.
Low
Report
AnaptysBio, Inc. (NASDAQ: ANAB) had its price target lowered by analysts at JPMorgan Chase & Co. from $30.00 to $28.00. They now have a "neutral" rating on the stock.
3/18
07:02 am
anab
Industry Analysts Just Made A Stunning Upgrade To Their AnaptysBio, Inc. (NASDAQ:ANAB) Revenue Forecasts [Yahoo! Finance]
Low
Report
Industry Analysts Just Made A Stunning Upgrade To Their AnaptysBio, Inc. (NASDAQ:ANAB) Revenue Forecasts [Yahoo! Finance]
3/16
11:28 am
anab
Jemperli Cancer Drug: What To Know As GSK Says It Improves Survival For Uterine Cancer Patients [Forbes]
Low
Report
Jemperli Cancer Drug: What To Know As GSK Says It Improves Survival For Uterine Cancer Patients [Forbes]
3/16
08:15 am
anab
Positive RUBY phase III data show potential for Jemperli (dostarlimab-gxly) combinations in more patients with primary advanced or recurrent endometrial cancer [Yahoo! Finance]
Low
Report
Positive RUBY phase III data show potential for Jemperli (dostarlimab-gxly) combinations in more patients with primary advanced or recurrent endometrial cancer [Yahoo! Finance]
3/12
07:26 am
anab
AnaptysBio, Inc. (NASDAQ: ANAB) was upgraded by analysts at Wedbush from a "neutral" rating to an "outperform" rating. They now have a $34.00 price target on the stock, up previously from $20.00.
Medium
Report
AnaptysBio, Inc. (NASDAQ: ANAB) was upgraded by analysts at Wedbush from a "neutral" rating to an "outperform" rating. They now have a $34.00 price target on the stock, up previously from $20.00.
3/11
04:27 pm
anab
Anaptys Announces Fourth Quarter and Full Year 2023 Financial Results and Provides Business Update [Yahoo! Finance]
High
Report
Anaptys Announces Fourth Quarter and Full Year 2023 Financial Results and Provides Business Update [Yahoo! Finance]
3/11
04:15 pm
anab
Anaptys Announces Fourth Quarter and Full Year 2023 Financial Results and Provides Business Update
High
Report
Anaptys Announces Fourth Quarter and Full Year 2023 Financial Results and Provides Business Update
2/29
09:15 am
anab
Anaptys to Present at TD Cowen’s 44th Annual Health Care Conference and 2024 AAD Annual Meeting
Low
Report
Anaptys to Present at TD Cowen’s 44th Annual Health Care Conference and 2024 AAD Annual Meeting
2/28
11:25 am
anab
AnaptysBio, Inc. (ANAB) Expected to Beat Earnings Estimates: Should You Buy? [Yahoo! Finance]
Low
Report
AnaptysBio, Inc. (ANAB) Expected to Beat Earnings Estimates: Should You Buy? [Yahoo! Finance]
2/26
08:09 am
anab
AnaptysBio, Inc. (NASDAQ: ANAB) is now covered by analysts at BTIG Research. They set a "buy" rating and a $55.00 price target on the stock.
Low
Report
AnaptysBio, Inc. (NASDAQ: ANAB) is now covered by analysts at BTIG Research. They set a "buy" rating and a $55.00 price target on the stock.
2/21
02:18 pm
anab
Stifel starts AnaptysBio at buy, cites upcoming catalysts [Seeking Alpha]
Low
Report
Stifel starts AnaptysBio at buy, cites upcoming catalysts [Seeking Alpha]
2/21
07:03 am
anab
AnaptysBio, Inc. (NASDAQ: ANAB) is now covered by analysts at Stifel Nicolaus. They set a "buy" rating and a $50.00 price target on the stock.
Medium
Report
AnaptysBio, Inc. (NASDAQ: ANAB) is now covered by analysts at Stifel Nicolaus. They set a "buy" rating and a $50.00 price target on the stock.
2/19
08:01 am
anab
Strength Seen in AnaptysBio, Inc. (ANAB): Can Its 5.9% Jump Turn into More Strength? [Yahoo! Finance]
Low
Report
Strength Seen in AnaptysBio, Inc. (ANAB): Can Its 5.9% Jump Turn into More Strength? [Yahoo! Finance]
2/16
07:28 am
anab
AnaptysBio, Inc. (NASDAQ: ANAB) is now covered by analysts at Piper Sandler. They set an "overweight" rating and a $80.00 price target on the stock.
Neutral
Report
AnaptysBio, Inc. (NASDAQ: ANAB) is now covered by analysts at Piper Sandler. They set an "overweight" rating and a $80.00 price target on the stock.
1/31
09:15 am
anab
Anaptys to Present at Guggenheim’s 6th Annual Biotechnology Conference
Medium
Report
Anaptys to Present at Guggenheim’s 6th Annual Biotechnology Conference